Submit Manuscript  

Article Details


Utilization of Lipid-based Nanoparticles to Improve the Therapeutic Benefits of Bortezomib

[ Vol. 20 , Issue. 6 ]

Author(s):

Mitra Korani, Shahla Korani, Elham Zendehdel, Mahmoud R. Jaafari, Thozhukat Sathyapalan and Amirhossein Sahebkar*   Pages 643 - 650 ( 8 )

Abstract:


Cancer is a condition where there is an uncontrolled growth of cells resulting in high mortality. It is the second most frequent cause of death worldwide. Bortezomib (BTZ) is a Proteasome Inhibitor (PI) that is used for the treatment of a variety of cancers. It is the first PI that has received the approval of the US Food and Drug Administration (FDA) to treat mantle cell lymphoma and multiple myeloma. High incidence of sideeffects, limited dose, low water solubility, fast clearance, and drug resistance are the significant limitations of BTZ. Therefore, various drug delivery systems have been tried to overcome these limitations of BTZ in cancer therapy. Nanotechnology can potentially enhance the aqueous solubility of BTZ, increase its bioavailability, and control the release of BTZ at the site of administration. The lipid-based nanocarriers, such as liposomes, solid lipid NPs, and microemulsions, are some of the developments in nanotechnology, which could potentially enhance the therapeutic benefits of BTZ.

Keywords:

Lipid-based nanocarriers, liposomes, solid lipid nanoparticles, microemulsion, Bortezomib, a proteasome inhibitor.

Affiliation:

Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Research Center of Oils and Fats, Kermanshah University of Medical Sciences, Kermanshah, Department of Biochemistry and Biophysics, Faculty of Sciences, Mashhad Branch, Islamic Azad University, Mashhad, Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Department of Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Hull, Halal Research Center of IRI, FDA, Tehran



Read Full-Text article